View our corporate fact sheet:View Corporate Fact Sheet
Learn more about our product pipeline:
View Product Pipeline
Aries Pharmaceuticals, Inc. (Aries) is a wholly owned subsidiary of Aries Pharmaceuticals, Ltd., which is a wholly owned Subsidiary of Cosmo Pharmaceuticals, NV, a specialty pharmaceutical and medical device company focused on developing and commercializing best in class products in endoscopy and to treat gastrointestinal diseases. The Aries portfolio of four products, three of which are still in development, is licensed from Cosmo Pharmaceuticals N.V. to Aries Pharmaceuticals, Ltd.
Our products have the potential to improve patient outcomes in endoscopy and in the treatment of select gastrointestinal disorders.
Our first marketed product in the U.S., Eleview® launched in May 2017, is an FDA 510(k) cleared class ll medical device. Eleview is an injectable composition intended for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions prior to excision.
Products in Development
- Methylene Blue MMX™* is a novel oral formulation of methylene blue dye. MMX® technology is a delayed and controlled release formulation that allows for the delivery of methylene blue along the entire length of the colon, with the objective of enabling endoscopists to better detect and visualize pre-cancerous and cancerous lesions.
- Aemcolo (Rifamycin SV MMX®)*, the antibiotic rifamycin SV engineered with the MMX technology, is being studied for travelers’ diarrhea, IBS-D, and uncomplicated diverticulitis.
- Remimazolam* is an ultra-short-acting benzodiazepine that is being studied for its role in sedation of patients undergoing colonoscopy and bronchoscopy.
*Methylene Blue MMX, Rifamycin SV MMX and Remimazolam are under investigation and the safety and effectiveness of the product(s) has not been established.